Simple resection of truncal desmoid tumors: A case series

Nishida,Yoshihiro; Tsukushi,Satoshi; Urakawa,Hiroshi; Hamada,Shunsuke; Kozawa,Eiji; Ikuta,Kunihiro; Ishiguro,Naoki

doi:10.3892/ol.2016.4792

Simple resection of truncal desmoid tumors: A case series

Authors:
- Yoshihiro Nishida
- Satoshi Tsukushi
- Hiroshi Urakawa
- Shunsuke Hamada
- Eiji Kozawa
- Kunihiro Ikuta
- Naoki Ishiguro
View Affiliations

Affiliations: Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan
Published online on: June 28, 2016 https://doi.org/10.3892/ol.2016.4792
Pages: 1564-1568

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Desmoid tumors of the extra-abdominal and abdominal wall have been associated with morbidity due to the aggressive nature of the surgery and high recurrence rates. Surgery that does not cause functional impairment is desired for patients with desmoid tumors. In the present study, among patients with desmoid tumors who were prospectively and consecutively treated with identical conservative treatment with meloxicam, a selected patients of patients were treated with less invasive surgery than wide-resection. Out of 60 patients pathologically diagnosed with desmoid tumors, 9 patients with tumors refractory to conservative treatment and 4 patients who refused to receive this type of treatment were treated with planned simple resection. Subsequently, the clinical outcome of the patients and the mutational status of the catenin β‑1 (CTNNB1) gene in the tumors were analyzed. The mean age of the 13 patients that underwent planned simple resection was 39 years, and the tumors were located in the abdominal wall in 6 cases, the chest wall in 4 cases and the neck in 3 cases. All excised specimens were evaluated and positive microscopic margins were identified; however, during the mean follow‑up period of 30 months, 12/13 cases, 7 of which had T41A mutations and 5 of which had no mutations (wild‑type), did not develop recurrence. Only 1 initial case with an S45F mutation in the CTNNB1 gene developed recurrence. The results of the present prospectively treated with simple resection and retrospectively analyzed study suggest that planned simple resection could serve as a therapeutic modality for extraperitoneal desmoid tumors, particularly truncal ones with a wild-type or T41A mutational status.

View Figures

View References

1	Reitamo JJ, Scheinin TM and Häyry P: The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 151:230–237. 1986. View Article : Google Scholar : PubMed/NCBI
2	Ballo MT, Zagars GK, Pollack A, Pisters PW and Pollack RA: Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 17:158–167. 1999.PubMed/NCBI
3	Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M and Rosai J: Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution. J Clin Oncol. 21:1390–1397. 2003. View Article : Google Scholar : PubMed/NCBI
4	Huang K, Fu H, Shi YQ, Zhou Y and Du CY: Prognostic factors for extra-abdominal and abdominal wall desmoids: A 20-year experience at a single institution. J Surg Oncol. 100:563–569. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, Lazar AA, Patel SR, Benjamin RS and Pollock RE: Optimizing treatment of desmoid tumors. J Clin Oncol. 25:1785–1791. 2007. View Article : Google Scholar : PubMed/NCBI
6	Merchant NB, Lewis JJ, Woodruff JM, Leung DH and Brennan MF: Extremity and trunk desmoid tumors: A multifactorial analysis of outcome. Cancer. 86:2045–2052. 1999. View Article : Google Scholar : PubMed/NCBI
7	Nuyttens JJ, Rust PF, Thomas CR Jr and Turrisi AT III: Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer. 88:1517–1523. 2000. View Article : Google Scholar : PubMed/NCBI
8	Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, Bonvalot S, Stoeckle E, Guillou L, Le Cesne A, et al: Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy according to tumor presentation. J Clin Oncol. 29:3553–3558. 2011. View Article : Google Scholar : PubMed/NCBI
9	Shido Y, Nishida Y, Nakashima H, Katagiri H, Sugiura H, Yamada Y and Ishiguro N: Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg. 129:929–933. 2009. View Article : Google Scholar : PubMed/NCBI
10	Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, Hartgrink HH, Cleton-Jansen AM, Domont J, Bovée JV, et al: CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study. Cancer. 119:3696–3702. 2013. View Article : Google Scholar : PubMed/NCBI
11	Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE and Lev D: Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 173:1518–1527. 2008. View Article : Google Scholar : PubMed/NCBI
12	Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, Szymonifka J, Yeap BY, Chen YL, Harmon DC, et al: β-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 18:1043–1049. 2013. View Article : Google Scholar : PubMed/NCBI
13	Nishida Y, Tsukushi S, Shido Y, Urakawa H, Arai E and Ishiguro N: Transition of treatment for patients with extra-abdominal desmoid tumors: Nagoya university modality. Cancers (Basel). 4:88–99. 2012. View Article : Google Scholar : PubMed/NCBI
14	Nishida Y, Tsukushi S, Shido Y, Wasa J, Ishiguro N and Yamada Y: Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: A pilot study. J Clin Oncol. 28:e107–e109. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hamada S, Futamura N, Ikuta K, Urakawa H, Kozawa E, Ishiguro N and Nishida Y: CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: A pilot study. PLoS One. 9:e963912014. View Article : Google Scholar : PubMed/NCBI
16	Poon R, Smits R, Li C, Jagmohan-Changur S, Kong M, Cheon S, Yu C, Fodde R and Alman BA: Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene. 20:451–460. 2001. View Article : Google Scholar : PubMed/NCBI
17	Nishida Y, Tsukushi S, Urakawa H, Arai E and Ishiguro N: Is it possible to identify clinically useful prognostic groups for patients with desmoid tumors? J Clin Oncol. 30:1390author reply 1391. 2012. View Article : Google Scholar : PubMed/NCBI
18	Hamada S, Urakawa H, Kozawa E, Futamura N, Ikuta K, Shimoyama Y, Nakamura S, Ishiguro N and Nishida Y: Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors. Tumour Biol. 35:4561–4566. 2014. View Article : Google Scholar : PubMed/NCBI
19	Bo N, Wang D, Wu B, Chen L and Ruixue Ma: Analysis of β-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis. Pediatr Dev Pathol. 15:173–178. 2012. View Article : Google Scholar : PubMed/NCBI
20	Dômont J, Salas S, Lacroix L, Brouste V, Saulnier P, Terrier P, Ranchère D, Neuville A, Leroux A, Guillou L, et al: High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: A potential molecular tool for disease management. Br J Cancer. 102:1032–1036. 2010. View Article : Google Scholar : PubMed/NCBI
21	Huss S, Nehles J, Binot E, Wardelmann E, Mittler J, Kleine MA, Künstlinger H, Hartmann W, Hohenberger P, Merkelbach-Bruse S, et al: β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology. 62:294–304. 2013. View Article : Google Scholar : PubMed/NCBI
22	Le Guellec S, Soubeyran I, Rochaix P, Filleron T, Neuville A, Hostein I and Coindre JM: CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: A study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol. 25:1551–1558. 2012. View Article : Google Scholar : PubMed/NCBI